Chronic Myelogenous Leukemia

Oncology·MeSH: Leukemia, Myelogenous, Chronic, BCR-ABL Positive

32 drugs in development·11 companies·6 clinical trials

Drug Pipeline by Phase

Approved(4)

Drug	Company
bosutinib	Impax Laboratories, LLC (IPXL)
bosutinib	SUNSET ISLAND GROUP (SUN)
busulfan	Amneal Pharmaceuticals, Inc. (AMRX)
busulfan	NEXUS BIOPHARMA INC (NEXS)

Phase 3(17)

Drug	Company
abl001 200mg qd	NOVARTIS AG (NVSEF)
abl001 200mg qd	Novartis AG (NVS)
abl001 40mg bid	NOVARTIS AG (NVSEF)
abl001 40mg bid	Novartis AG (NVS)
abl001 80mg qd	Novartis AG (NVS)
abl001 80mg qd	NOVARTIS AG (NVSEF)
asciminib single agent	NOVARTIS AG (NVSEF)
Blinatumomab	Assertio Holdings, Inc. (ASRT)
bosutinib	GH Research PLC (GHRS)
bosutinib	Novartis AG (NVS)
Cytarabine	Assertio Holdings, Inc. (ASRT)
Filgrastim	Assertio Holdings, Inc. (ASRT)
imatinib	GH Research PLC (GHRS)
Liposome-encapsulated Daunorubicin-Cytarabine	Assertio Holdings, Inc. (ASRT)
nilotinib	GH Research PLC (GHRS)
Ponatinib	ENANTA PHARMACEUTICALS INC (ENTA)
Vincristine	Assertio Holdings, Inc. (ASRT)

Phase 2(2)

Drug	Company
Pegfilgrastim	Assertio Holdings, Inc. (ASRT)
Ponatinib	Assertio Holdings, Inc. (ASRT)

Phase 1(3)

Drug	Company
Cytarabine	Structure Therapeutics Inc. (GPCR)
elvn-001	Enliven Therapeutics, Inc. (ELVN)
Vincristine	Structure Therapeutics Inc. (GPCR)

Phase 4(6)

Drug	Company
asciminib single agent	Novartis AG (NVS)
asciminib single agent pediatric formulation	Novartis AG (NVS)
asciminib single agent pediatric formulation	NOVARTIS AG (NVSEF)
bosutinib	Novartis AG (NVS)
imatinib	Novartis AG (NVS)
imatinib	Novartis AG (NVS)

BioSniper tracks 32 drugs in development for Chronic Myelogenous Leukemia across 11 companies.

There are 6 clinical trials targeting Chronic Myelogenous Leukemia tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.